Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals with osteoporosis

Journal of Bone and Mineral Metabolism

Volumn 28, Issue 2, 2010, Pages 233-239

  Ryder, Kathryn M ^a,b   Bobo Tanner, S ^c   Carbone, Laura ^a,b   Williams, John E ^d   Taylor, Henry M ^e   Bush, Andrew ^a   Pintea, Victorina ^a   Watsky, Mitchell A ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GREENVILLE HOSPITAL SYSTEM   (United States)

^e Tennessee Division of Mental Retardation Services   (United States)

Author keywords

Biomarkers; Developmental disabilities; Disuse osteoporosis; Institutionalized; Teriparatide

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ANTICONVULSIVE AGENT; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; PARATHYROID HORMONE[1-34]; RALOXIFENE; SALCATONIN; TESTOSTERONE; VITAMIN D; BONE DENSITY CONSERVATION AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERCALCEMIA; INSTITUTIONALIZATION; MALE; OSSIFICATION; OSTEOPOROSIS; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; AGED; BLOOD; BONE; BONE DEVELOPMENT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG EFFECT; DRUG MONITORING; HYPOKINESIA; MENTAL PATIENT; MIDDLE AGED; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TIME;

AGED; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCIUM; DRUG MONITORING; FEMALE; HUMANS; HYPERCALCEMIA; HYPOKINESIA; INJECTIONS, SUBCUTANEOUS; INSTITUTIONALIZATION; MALE; MENTALLY DISABLED PERSONS; MIDDLE AGED; OSTEOGENESIS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; TERIPARATIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952479638     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-009-0123-1     Document Type: Article

References (29)

1. Ryder KM, Williams J, Womack C, Nayak NG, Nasef S, Bush A, Tylavsky FA, Carbone L (2003) Appendicular fractures: a significant problem among institutionalized adults with developmental disabilities. Am J Ment Retard 108:340-346
2. Leslie WD, Pahlavan PS, Tsang JF, Lix LM (2009) Prediction of hip and other osteoporotic fractures from hip geometry in a large clinical cohort. Osteoporos Int
3. Nilsson OS, Lindholm TS, Elmstedt E, Lindback A, Lindholm TC (1986) Fracture incidence and bone disease in epileptics receiving long-term anticonvulsant drug treatment. Arch Orthop Trauma Surg 105:146-149
4. Tyler CV Jr, Snyder CW, Zyzanski S (2000) Screening for osteoporosis in community-dwelling adults with mental retardation. Ment Retard 38:316-321
5. Jiang SD, Jiang LS, Dai LY (2006) Mechanisms of osteoporosis in spinal cord injury. Clin Endocrinol (Oxf) 65:555-565
6. Reilly S, Skuse D, Poblete X (1996) Prevalence of feeding problems and oral motor dysfunction in children with cerebral palsy: a community survey. J Pediatr 129:877-882
7. Li CY, Price C, Delisser K, Nasser P, Laudier D, Clement M, Jepsen KJ, Schaffler MB (2005) Long-term disuse osteoporosis seems less sensitive to bisphosphonate treatment than other osteoporosis. J Bone Miner Res 20:117-124
8. Zehnder Y, Risi S, Michel D, Knecht H, Perrelet R, Kraenzlin M, Zach GA, Lippuner K (2004) Prevention of bone loss in paraplegics over 2 years with alendronate. J Bone Miner Res 19:1067-1074
9. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282:637-645
10. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288:321-333
11. Turner RT, Evans GL, Lotinun S, Lapke PD, Iwaniec UT, Morey-Holton E (2007) Dose-response effects of intermittent PTH on cancellous bone in hindlimb unloaded rats. J Bone Miner Res 22:64-71
12. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
13. DeVivo MJ, Fine PR, Cutter GR, Maetz HM (1984) The risk of renal calculi in spinal cord injury patients. J Urol 131:857-860
14. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962-970
15. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB (2007) Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146:326-339
16. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226
17. Damilakis J, Perisinakis K, Gourtsoyiannis N (2001) Imaging ultrasonometry of the calcaneus: optimum T-score thresholds for the identification of osteoporotic subjects. Calcif Tissue Int 68:219-224
18. Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R (2001) Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16:925-931
19. Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH (2005) Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 20:1905-1911
20. Polednak AP (1975) Respiratory disease mortality in an institutionalised mentally retarded population. J Ment Defic Res 19:165-172
21. Cummings SR, Bates D, Black DM (2002) Clinical use of bone densitometry: scientific review. JAMA 288:1889-1897 (Pubitemid 35168145)
22. Eastell R, Krege JH, Chen P, Glass EV, Reginster JY (2006) Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 22:61-66
23. Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R (2006) Response rate of bone mineral density to teriparatide in post-menopausal women with osteoporosis. Bone 39:1268-1275
24. Miyauchi A, Matsumoto T, Shigeta H, Tsujimoto M, Thiebaud D, Nakamura T (2008) Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmeno-pausal osteoporosis: a 6-month dose-response study. J Bone Miner Metab 26:624-634
25. Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR (2009) Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int
26. Gilchrist NL, Frampton CM, Acland RH, Nicholls MG, March RL, Maguire P, Heard A, Reilly P, Marshall K (2007) Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 92:1385-1390
27. Watanabe Y, Ohshima H, Mizuno K, Sekiguchi C, Fukunaga M, Kohri K, Rittweger J, Felsenberg D, Matsumoto T, Nakamura T (2004) Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest. J Bone Miner Res 19:1771-1778
28. Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH (2006) Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 39:237-243
29. Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM (2006) The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 166:1209-1217